## 1 Mediators between body mass index and atrial fibrillation: a Mendelian

### 2 Randomization study

- <sup>3</sup> Ziting Gao, M.D.<sup>1</sup>, Jun Xiao, M.D., Ph.D<sup>2,3\*</sup>, Wuqing Huang, M.D., Ph.D<sup>1\*</sup>
- <sup>4</sup> <sup>1</sup> Department of Epidemiology and Health Statistics, School of Public Health, Fujian
- 5 Medical University, Fuzhou, Fujian, China.
- <sup>2</sup> Department of Cardiovascular Surgery, Union Hospital, Fujian Medical University,
- 7 Fuzhou, Fujian, China.
- 8 <sup>3</sup> Key Laboratory of Cardio-Thoracic Surgery, Fujian Medical University, Fujian,
- 9 China.
- 10 Short title: Mediators between BMI and atrial fibrillation.
- 11 \*Share the senior authorship.
- 12 Correspondence: Wuqing Huang & Jun Xiao
- 13 Wuqing Huang
- 14 Fujian Medical University,
- 15 No 1, Xue Yuan Road, University Town, 350108
- 16 Fuzhou City, Fujian Province, China.
- 17 Email: <u>wuqing.huang@fjmu.edu.cn</u> Telephone: +8617338896101
- 18 Jun Xiao
- 19 Fujian Medical University Union Hospital,
- 20 No. 29 Xinquan Road, Fuzhou City, 350001,
- 21 Fujian Province, China.
- 22 Email: <u>xiaojun@fjmu.edu.cn</u> Telephone: +8618229908473

23 **Word count:** abstract (231), text (2891), figures (53), tables (0)

24	Abbreviations: AF, A	trial fibrillation;	CRP C-reactive	protein; BMI, boo	ly mass index;
----	----------------------	---------------------	----------------	-------------------	----------------

- 25 MR, Mendelian randomization; GWASs, Genome-Wide Association Studies; LDL-C,
- 26 low-density lipoprotein cholesterol; HDL-C high-density lipoprotein cholesterol; TC
- 27 total cholesterol; TG triglycerides; GIANT, Genetic Investigation of ANthropometric
- 28 Traits; SNPs, single nucleotide polymorphisms; IVW-MR, inverse-variance weighted
- 29 mendelian randomization; PERM, percentage of excess risk mediated; OR, odds ratio.
- 30

31

32

# 33 Abstract

34	Background: Although obesity is a recognized risk factor of atrial fibrillation (AF),
35	the mechanisms are not fully understood. Thus, we aimed to identify the potential
36	mediators between body mass index (BMI) and AF.
37	Methods: We conducted a two-sample Mendelian randomization (MR) analysis using
38	publicly available summary-level data from genome-wide association studies.
39	Univariable MR analyses were applied to identify potential mediators, and then the
40	multivariable MR analyses were conducted to explore the mediated roles of
41	circulating cytokines, metabolic markers and comorbidities in the association between
42	BMI and AF.
43	Results: This MR study found a significant causal association between BMI and AF
44	(OR=1.41, 95%CI=1.33-1.50; P<0.001), which was attenuated to 1.21
45	(95%CI=1.03-1.43) after being adjusted for leptin, in which 48.78% excess risk was
46	mediated. After further adjustment for leptin and sleep apnoea or coronary heart
47	disease, the association was attenuated to null (adjusted for leptin and sleep apnoea:
48	OR=1.05, 95%CI=0.85-1.30; adjusted for leptin and coronary heart disease: OR=1.08,
49	95%CI=0.90-1.30), resulting in 87.80% and 80.49% excess risk being mediated,
50	respectively.
51	Conclusion: These results identified an important mediated role of leptin, particularly
52	for individuals with sleep apnoea or coronary heart disease, providing some clues for
53	the underlying mechanisms behind the impact of obesity on AF risk.
54	Funding: Natural Science Foundation of Fujian Province (grant no. 2022J01706) and

# 55 the Start-up Fund for high-level talents of Fujian Medical University

- 56 (XRCZX2021026).
- 57 Keywords: obesity, atrial fibrillation, leptin, mendelian randomization

## 58 Introduction

59	Atrial fibrillation (AF) is the most common type of arrhythmia and associated with
60	significant elevated risk of morbidity and mortality, resulting in major public health
61	burden and referred to as a cardiovascular epidemic of the 21st century. The incidence
62	is continuously increasing, the Framingham Heart Study has reported a threefold
63	increase in the incidence of AF during the past 50 years. <sup>1</sup> AF is closely related to a
64	range of classic cardiovascular risk factors, including modifiable lifestyle factors (eg,
65	obesity, hypertension, diabetes, coronary artery disease, hyperthyroidism, kidney
66	disease),and non-modifiable factors (eg, age, ethnic). <sup>2</sup> Although a number of risk
67	factors have been linked to a higher risk of AF, the etiology has not been clarified yet.
68	Obesity is a well-established risk factor for AF. <sup>3-8</sup> ARIC (Atherosclerosis Risk In
69	Communities) study reported that nearly 20% of atrial fibrillation cases can be
70	attributed to overweight or obesity.9 However, the underlying pathways behind
71	obesity and AF remained unclear. Several mechanisms have been proposed to explain
72	this link. <sup>2</sup> For example, obesity always co-exists with multiple metabolic disorders,
73	such as dyslipidemia, hypertension and diabetes, all of which have ever been reported
74	to increase the risk of AF. Prior epidemiological studies found that obese adults were
75	predisposed to some comorbidities, such as coronary heart disease, obstructive sleep
76	apnoea, hyperthyroidism and so on, besides, complex links were reported between AF
77	and these comorbidities, indicating a potential mediated role of comorbidities between
78	obesity and AF. Furthermore, obesity is related to the circulating level of
79	adipocyte-derived cytokines (i.e., adipokines) as well as inflammatory cytokines.

Circulating leptin (the marker of leptin resistance) and C reactive protein (CRP) (an
important marker of inflammation) are always correlated, increased level of both is
common in obesity and independently associated with risk of multiple cardiovascular
diseases, including AF.<sup>10,11</sup>

Given that obesity is becoming an epidemic with an estimation of one third of 84 85 the population globally being overweight or obese, targeting obesity and its pathways is a promising strategy to largely reduce the incidence of AF.<sup>12</sup> While obesity is a 86 87 complex condition, evidence of "obesity paradox" is emerging for cardiovascular diseases, for example, some studies found a more favorable prognosis in AF patients 88 with a higher body mass index (BMI).<sup>13</sup> Thus, it is important to fully understand the 89 possible pathways in the association of BMI and AF. There are a paucity of studies 90 91 exploring the potential mediators between obesity and AF, which is challenging to be 92 studied in traditional observational epidemiological studies due to the inherent 93 problems of unmeasurable confounding factors and reverse causality. Mendelian 94 randomization (MR) approach complements traditional epidemiological methods as it contributes to overcoming these flaws by using genetic variants as instrumental 95 variables.<sup>14</sup> Therefore, in this study, we aimed to extensively explore the potential 96 97 mediators and identify the dominating mediators in the relationship between BMI and AF via multivariable MR study. 98

99 Methods

100 Study design

101 We used publicly available summary-level data from Genome-Wide Association

6

102 Studies (GWAS) (**Supplementary Table 1**) to conduct two-sample MR study. MR 103 uses genetic variants strongly correlated with exposure factors as instrumental 104 variables (IVs) to estimate causal effects between exposure and outcomes.<sup>14</sup> All 105 publicly available studies used in this research had been approved by the relevant 106 institutional review boards and participants had provided informed consents.

107 According to findings from previous studies regarding risk factors of AF, we 108 categorized the potential mediators into three classes in the present study, including 109 circulating cytokines, metabolic markers and comorbidities. Circulating cytokines include leptin, adiponectin, resistin and CRP; Metabolic markers include low-density 110 lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total 111 112 cholesterol (TC), triglycerides (TG), fasting blood glucose, systolic blood pressure 113 and diastolic blood pressure; Obesity-related comorbidities include sleep apnoea, 114 coronary heart disease, stroke, chronic kidney disease and hyperthyroidism. The 115 univariable MR analyses were first applied to investigate the total effect of BMI on 116 AF, and to evaluate the causal relationship between BMI and potential mediators as 117 well as between potential mediators and AF to identify the significant mediators. Next, 118 the multivariable MR analyses were conducted to assess the mediated effects of these 119 significant mediators between BMI and AF.

120 Data sources

121 The GWAS summary-level data of BMI was obtained from the Genetic Investigation 122 of ANthropometric Traits (GIANT) consortium, which is a meta-analysis of 123 genome-wide association studies to investigate the genetic associations with height

and body mass index in approximately 700,000 individuals of European ancestry.<sup>15</sup> 124 125 For atrial fibrillation, we used the latest meta-analysis of GWAS, which compared a 126 total of 60,620 individuals with atrial fibrillation with 970,216 control individuals of 127 European ancestry from six contributing studies, including the Nord-Trøndelag Health Study, the Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in 128 Europe study, the Michigan Genomics Initiative, DiscovEHR, UK Biobank, and the 129 Atrial Fibrillation Genetics Consortium.<sup>16</sup> The GWAS summary-level data of leptin 130 derived from the study covering 56,802 samples and 231,001 SNPs.<sup>17</sup> For other 131 potential mediators, we used GWAS summary data from CARDIoGRAMplusC4D for 132 133 coronary heart disease, ISGC Consortium for stroke, FinnGen Consortium for sleep 134 apnoea, ADIPOGen Consortium for adiponectin, Global Lipids Genetics Consortium 135 for lipids, International Consortium of Blood Pressure for blood pressure, and UK 136 biobank for hyperthyroidism. Details of data resources are presented in the 137 Supplementary Table 1.

#### 138 Genetic instruments selection

We selected all single nucleotide polymorphisms (SNPs) significantly related to BMI or each mediator from corresponding GWAS summary-level data as instrumental variables to proxy each exposure, the statistical significance was set at genome-wide significance levels ( $P < 5 * 10^{-8}$ ). SNPs in linkage disequilibrium were excluded, which was estimated by  $r^2$  at the cutoff value of 0.001 within 10,000 kb window using European reference panel from 1000 Genomes Project.

#### 145 Statistical analyses

#### 146 Primary analyses

147 Two-sample MR analyses were performed by using "TwoSampleMR" R package. In 148 this study, inverse-variance weighted mendelian randomization (IVW-MR) method 149 was applied to obtain the estimates of the causal associations between exposure and outcomes, which is the most widely used approach. The univariable MR analyses 150 151 were first conducted to evaluate the causal relationship between BMI and AF. Next, 152 we further applied the univariable MR analyses to identify the potential mediated 153 pathways between BMI and AF by screening out the mediators which had causal 154 associations with both BMI and AF. At last, the mediation effect of these identified 155 mediators between BMI and AF was assessed by including these mediators one by 156 one in each multivariable MR model. To further investigate the mediated role of these 157 factors, we calculated the percentage of excess risk mediated (PERM) with odds ratio 158 (OR) as the formula below:

$$PERM = \frac{OR - OR_{(\text{mediator adjusted})}}{OR - 1} \times 100$$

159

### 160 Sensitivity analyses

Several sensitivity analyses were performed to assess the robustness of the observed results. The Cochrane Q test was used to test for the heterogeneity of instrumental variables, in which p<0.05 indicates the presence of heterogeneity. The MR-Egger regression intercept and the MR-PRESSO global test was used to assess the horizontal pleiotropy of instrumental variables. Horizontal pleiotropy refers to the fact that SNPs used as instrumental variables can influence the outcome by means other than exposure. In MR-Egger regression, the intercept indicates horizontal pleiotropy; the

168 closer the value is to 0, the less likely it is that the instrumental variable is 169 horizontally pleiotropic, with p < 0.05 suggesting possible horizontal pleiotropy. In 170 MR-PRESSO analysis, global test can be used to test for the presence of horizontal 171 pleiotropy where P < 0.05 indicates the presence of horizontal pleiotropy. If the horizontal pleiotropy was present, we further identified the horizontal pleiotropic 172 173 outliers in MR-PRESSO analysis and applied distortion test to test the difference in 174 the estimates before and after outlier removal, where p > 0.05 indicates no statistically 175 significant difference. To further identify the SNP primarily affected by pleiotropy, 176 leave-one-out sensitivity analysis was conducted. This involved removing one SNP at 177 a time and calculating the meta-effect of the remaining SNPs. The analysis observed 178 whether there were any changes in the results after the removal of one SNP. SNPs 179 were then rejected one by one to determine whether they significantly affected the 180 results. R software (version 4.1.0) was used to perform all analyses in this study.

181 **Results** 

182 Univariable MR study for the association of BMI with AF and potential
183 mediators

As shown in **Figure 1** and **Supplementary Table 2**, the univariable MR analysis showed a significant causal association between BMI and AF (OR=1.41, 95%CI=1.33-1.50; P<0.001). For the association with potential mediators, we found that higher level of genetically-predicted BMI was significantly associated with a lower level of systolic blood pressure (OR= 0.58, 95%CI=0.35-0.96; P=0.032), diastolic blood pressure (OR=0.62, 95%CI=0.46-0.84; P=0.002) and with a higher

<ul> <li>191 95%CI=1.02-2.16; P=0.008),CRP (OR=1.43, 95%CI=1.37-1.49;P&lt;0.001) and</li> <li>192 higher incidence of sleep apnoea (OR=2.13, 95%CI=1.93-2.35; P&lt;0.001), corona</li> </ul>	09,	
higher incidence of sleep apnoea (OR=2.13, 95%CI=1.93-2.35; P<0.001), corona	а	
	ıry	
193 heart disease (OR=1.54, 95%CI=1.43-1.66; P<0.001), stroke (OR=1.1	22,	
95%CI=1.15-1.30; P<0.001), and CKD (OR=1.27, 95%CI=1.16-1.40; P<0.001).		
195 Univariable MR study for the association of potential mediators with AF		

197 observed significant associations between genetically-predicted higher level of leptin

As shown in Figure 2 and Supplementary Table 3, the univariable MR analysis

198 (OR=1.31, 95%CI=1.10-1.55; P=0.002), higher level of systolic blood pressure

199 (OR=1.02, 95%CI=1.01-1.02; P<0.001), higher level of diastolic blood pressure

- 200 (OR=1.03, 95%CI=1.02-1.04; P<0.001), diagnosis of sleep apnoea (OR=1.18,
- 201 95%CI=1.07-1.30; P=0.001) or coronary heart disease (OR=1.11, 95%CI=1.05-1.17;
- P < 0.001) and higher incidence of AF.

196

#### 203 Multivariable MR study for the association of BMI with AF

204 Univariable MR studies identified several factors related to both BMI and AF, 205 including leptin, systolic blood pressure, diastolic blood pressure, sleep apnoea and coronary heart disease, the multivariable MR analyses were performed to assess the 206 207 mediation effect of these factors. As shown in Figure 3 and Supplementary Table 4, 208 the observed association between BMI and AF was attenuated from 1.41 209 (95%CI=1.33-1.50) to 1.21 (95%CI=1.03-1.43) after being adjusted for leptin, in 210 which 48.78% excess risk was mediated. After being adjusted for sleep apnoea or 211 coronary heart disease, the association was attenuated to 1.32(95%CI=1.23-1.43) or

1.33(95%CI=1.26-1.42), respectively. Furthermore, the association between BMI and AF was attenuated to null when being adjusted for leptin and each comorbidity (adjusted for leptin and sleep apnoea: OR = 1.05, 95%CI= 0.85-1.30; adjusted for leptin and coronary heart disease: OR = 1.08, 95%CI= 0.90-1.30), resulting in 87.80% and 80.49% excess risk being mediated, respectively. The observed association between BMI and AF did not change significantly after being adjusted for systolic blood pressure, diastolic blood pressure.

#### 219 Sensitivity analyses

220 The results of sensitivity analyses are present in **Supplementary files.** The scatter 221 plots of the main results showed similar results across different MR methods, 222 suggesting the robustness of the main results (Supplementary Figure 1). The 223 Cochrane Q test showed that potential heterogeneity was present in most analyses 224 except for BMI on CKD, leptin on AF, adiponectin on AF, sleep apnoea on AF, CKD 225 on AF and hyperthyroidism on AF. While leave-one-out analyses suggested that 226 heterogeneity played a small role in the main results (Supplementary Figure 2-6). 227 The results of MR-PRESSO analysis indicated the presence of horizontal pleiotropy 228 in most analyses (P < 0.05) while results from distortion test suggested that the 229 presence of horizontal pleiotropy had little impact on the most results (P>0.05) since 230 there was no statistically significant difference in results after outlier removal. Besides, 231 MR-Egger intercept analysis also suggested the absence of horizontal pleiotropy for 232 most reported results (p>0.05) except BMI on coronary heart disease and BMI on 233 hyperthyroidism.

## 234 **Discussion**

235 This MR study found causal relationship between BMI and AF, and identified leptin, 236 sleep apnoea and coronary heart disease as the mediators between BMI and AF. Specifically, around half of excess risk of AF related to obesity was mediated by 237 circulating leptin. Furthermore, after adjustment for leptin and specific comorbidity 238 239 (ie. sleep apnoea or coronary heart disease), the association between BMI and AF 240 completely declined to null, indicating that targeting obesity-induced leptin resistance 241 may be a promising strategy in preventing AF, especially for individuals with sleep 242 apnoea or coronary heart disease.

Obesity has been well established as an important risk factor for AF.<sup>3-8</sup> Both 243 traditional observational epidemiological studies and MR studies have provided 244 245 consistent evidence that obesity is associated with significant excess risk of AF. While 246 the efficacy of weight-loss intervention in AF prevention was less well established, 247 elucidating the underlying pathways between BMI and AF may contribute to providing a more precise strategy for AF prevention.<sup>18,19</sup> We also found similar results 248 249 in terms of the positive association between BMI and AF, what's more, circulating leptin was identified as a dominating mediator in the BMI-AF association in present 250 251 study.

Leptin, produced by adipose tissue, holds various regulatory functions in metabolism, immunity, and inflammation.<sup>20</sup> It is reported that obesity leads to dramatic rise in circulating levels of leptin, and some experiments revealed that the reduction of leptin levels can impede the progression of obesity.<sup>21</sup> Elevated leptin

256	levels were demonstrated to be a cardiovascular risk factor. <sup>22-24</sup> Some studies have
257	reported the effect of leptin on AF but provided conflicting conclusions. For example,
258	a case-control study found that individuals with AF had higher serum leptin levels
259	compared to the control group. <sup>25</sup> A MR study extensively explored the associations
260	between visceral adipose tissue, circulating protein biomarkers and risk of
261	cardiovascular diseases where a positive relationship between visceral fat, leptin
262	levels and the risk of AF was observed. <sup>26</sup> However, a prospective cohort study of
263	postmenopausal women did not uncover a significant correlation between leptin or
264	adiponectin and risk of AF. <sup>27</sup> The exact mechanism by which leptin elevates the risk
265	of AF remains unclear, although there were some hypotheses. For example,
266	hyperleptinemia and leptin resistance, both associated with obesity, may contribute to
267	the growth of left ventricular hypertrophy. <sup>28</sup> A review reveals that dysfunction of the
268	leptin signaling pathway is a significant contributor to obesity and related metabolic
269	disorders and the effects of the leptin signaling pathway on the cardiovascular system
270	are mediated through the modulation of cardiomyocyte and endothelial cell function,
271	among other mechanisms. <sup>29</sup> Animal experiments suggests that the signaling of leptin
272	plays a role in the development of atrial fibrosis and the occurrence of AF triggered
273	by angiotensin II or high-fat diet. <sup>30,31</sup>

It is surprising that the observed BMI-AF association completely declined to null in this study after adjustment for leptin and some comorbidity, such as sleep apnoea and atherosclerotic diseases (eg., coronary heart disease).

277

Obstructive sleep apnoea is a prevalent complication among individuals with

obesity.<sup>32,33</sup> A review has shown that obese individuals suffering from obstructive 278 sleep apnoea have higher level of leptin compared to those without, indicating a 279 positive relationship between obstructive sleep apnoea and leptin resistance.<sup>34</sup> 280 Additionally, previous research suggests that the disruption of leptin signaling in 281 282 individuals with obstructive sleep apnoea may result in oxidative stress and increase the risk of cardiovascular diseases.<sup>35</sup> A prospective analysis found that nearly half of 283 AF patients suffered from sleep apnoea, while only 32% of the control group did.<sup>36</sup> 284 285 Some mechanisms behind the association between obstructive sleep apnoea and the increased risk of AF have been proposed, including recurrent nocturnal 286 287 hypoxia/hypercapnia, surges in sympathetic tone and blood pressure during apneic episodes, and increased inflammation.<sup>37,38</sup> These studies suggested interconnects 288 289 between obesity, leptin, sleep appoea and AF. This study found that the effect of 290 obesity on AF was totally mediated by leptin and sleep apnoea, indicating that 291 targeting leptin resistance induced by obesity and sleep apnoea may be an effective 292 strategy for preventing AF.

Obesity is also associated with coronary heart disease, a risk factor for AF. Leptin secreted by adipose tissue may contribute to the development of atherosclerosis by affecting some types of cells, which may lead to the development of coronary heart disease.<sup>24</sup> For example, previous studies suggested that leptin had the potential to enhance platelet aggregation, while which was only observed in obese individuals, suggesting the prothrombotic effect of leptin is probably restricted to individuals with obesity-induced leptin resistance and acts as a mediator between

obesity and cardiovascular diseases.<sup>10</sup> Similarly, this study found that the effect of obesity on AF was totally mediated by leptin and atherosclerotic diseases, suggesting that targeting obesity-induced leptin resistance may be effective in AF prevention through the inhibition of platelet aggregation among individuals at high risk of atherosclerotic diseases or with a history of atherosclerotic diseases. Besides, leptin may directly affect coronary endothelial cells by increasing the expression of tissue factor and cellular adhesion molecules.<sup>39</sup>

307 A major advantage of the study was that MR design could reduce the impact of 308 confounding factors and avoid reverse causality as compared with traditional 309 observational epidemiological studies, which can provide complementary evidence 310 for the observational findings and examine the causal relationships between exposure, 311 mediators and outcome. To our knowledge, this is the first MR study to extensively 312 explore the potential mediating pathways between BMI and AF. However, there are 313 several limitations of this study. First, the GWAS summary data used in this study are 314 derived from relevant studies based on European populations, so the generalization of 315 these findings is limited and further studies are needed in populations of other ethnicities. Second, individual-level GWAS data are not publicly available, we are 316 317 thus not able to examine the associations in subgroup population. For example, 318 previous study showed that there were sex differences in leptin levels, stratified 319 analysis by sex may provide more information regarding the sex-specific mediating 320 role of leptin. Third, sensitivity analyses showed that some instrumental variables 321 may have horizontal pleiotropy, therefore the influence of potential horizontal

322 pleiotropy on the results cannot be completely ruled out.

323	In conclusion, this MR study identified leptin as an important mediator between
324	BMI and AF, suggesting that targeting leptin resistance may be crucial for developing
325	effective prevention and treatment strategies to reduce the risk of obesity-related AF,
326	particularly for individuals with sleep apnoea or coronary heart disease.
327	Contributors: All authors were responsible for the study concept and design. WH
328	obtained funding. ZG did the statistical analysis and drafted the manuscript. WH and
329	JX critically revised the manuscript. All authors gave the final approval and agreed to
330	be accountable for all aspects of work ensuring integrity and accuracy.
331	Data sharing statement: All raw data are available in the public repository IEU open
332	gwas project ( <u>https://gwas.mrcieu.ac.uk/</u> ).
333	Declaration of Competing Interest: The authors declare no competing interests.
334	Acknowledgments: We thank the patients and investigators who contributed to the UK
335	Biobank, GIANT Consortium, ADIPOGen, GLGC, International Consortium of Blood
336	Pressure, FinnGen biobank, CARDIoGRAMplusC4D Consortium, ISGC Consortium.
337	Funding Information: This work was supported by the Natural Science Foundation
338	of Fujian Province (grant no. 2022J01706) and the Start-up Fund for high-level talents
339	of Fujian Medical University (XRCZX2021026) to Dr. Wuqing Huang. The funder
340	had no role in study design, data collection and interpretation, or the decision to
341	submit the work for publication.

### 342 **References**

- Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation
   prevalence, incidence, risk factors, and mortality in the Framingham Heart
   Study: a cohort study. *Lancet.* 2015;386(9989):154-162.
- Kornej J, Borschel CS, Benjamin EJ, Schnabel RB. Epidemiology of Atrial
   Fibrillation in the 21st Century: Novel Methods and New Insights. *Circ Res.* 2020;127(1):4-20.
- Feng T, Vegard M, Strand LB, et al. Weight and weight change and risk of atrial
   fibrillation: the HUNT study. *Eur Heart J.* 2019;40(34):2859-2866.
- 4. Wong CX, Sullivan T, Sun MT, et al. Obesity and the Risk of Incident, Post-Operative, and Post-Ablation Atrial Fibrillation: A Meta-Analysis of 626,603 Individuals in 51 Studies. *JACC Clin Electrophysiol*. 2015;1(3):139-152.
- 5. Pathak RK, Middeldorp ME, Meredith M, et al. Long-Term Effect of 354 355 Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A 356 Long-Term Follow-Up Study (LEGACY). J Am Coll Cardiol. 357 2015;65(20):2159-2169.
- Larsson SC, Back M, Rees JMB, Mason AM, Burgess S. Body mass index and
   body composition in relation to 14 cardiovascular conditions in UK Biobank: a
   Mendelian randomization study. *Eur Heart J.* 2020;41(2):221-226.
- Chua W, Purmah Y, Cardoso VR, et al. Data-driven discovery and validation of
   circulating blood-based biomarkers associated with prevalent atrial fibrillation.
   *Eur Heart J.* 2019;40(16):1268-1276.
- Chatterjee NA, Giulianini F, Geelhoed B, et al. Genetic Obesity and the Risk of
   Atrial Fibrillation: Causal Estimates from Mendelian Randomization.
   *Circulation.* 2017;135(8):741-754.
- 367 9. Huxley RR, Lopez FL, Folsom AR, et al. Absolute and attributable risks of atrial 368 fibrillation in relation to optimal and borderline risk factors: the 369 Atherosclerosis Risk in Communities (ARIC) study. Circulation. 370 2011;123(14):1501-1508.
- 37110.Martin SS, Qasim A, Reilly MP. Leptin resistance: a possible interface of372inflammation and metabolism in obesity-related cardiovascular disease. J Am373Coll Cardiol. 2008;52(15):1201-1210.
- Hu YF, Chen YJ, Lin YJ, Chen SA. Inflammation and the pathogenesis of atrial
  fibrillation. *Nat Rev Cardiol.* 2015;12(4):230-243.
- 37612.Nalliah CJ, Sanders P, Kottkamp H, Kalman JM. The role of obesity in atrial377fibrillation. Eur Heart J. 2016;37(20):1565-1572.
- 378 13. Sandhu RK, Ezekowitz J, Andersson U, et al. The 'obesity paradox' in atrial
  379 fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in
  380 Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. *Eur Heart*381 J. 2016;37(38):2869-2878.
- Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology
   contribute to understanding environmental determinants of disease? *Int J Epidemiol.* 2003;32(1):1-22.

205	15.	Vanga I. Sidaranka I. Kampar KE at al. Mata analysis of ganama wida
385	15.	Yengo L, Sidorenko J, Kemper KE, et al. Meta-analysis of genome-wide
386		association studies for height and body mass index in approximately 700000
387	4.6	individuals of European ancestry. <i>Hum Mol Genet.</i> 2018;27(20):3641-3649.
388	16.	Nielsen JB, Thorolfsdottir RB, Fritsche LG, et al. Biobank-driven genomic
389		discovery yields new insight into atrial fibrillation biology. Nat Genet.
390		2018;50(9):1234-1239.
391	17.	Yaghootkar H, Zhang Y, Spracklen CN, et al. Genetic Studies of Leptin
392		Concentrations Implicate Leptin in the Regulation of Early Adiposity. Diabetes.
393		2020;69(12):2806-2818.
394	18.	Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and
395		cardiometabolic risk factor management on symptom burden and severity in
396		patients with atrial fibrillation: a randomized clinical trial. JAMA.
397		2013;310(19):2050-2060.
398	19.	Alonso A, Bahnson JL, Gaussoin SA, et al. Effect of an intensive lifestyle
399		intervention on atrial fibrillation risk in individuals with type 2 diabetes: the
400		Look AHEAD randomized trial. Am Heart J. 2015;170(4):770-777 e775.
401	20.	Flier JSJTYjob, medicine. Hormone resistance in diabetes and obesity: insulin,
402		leptin, and FGF21. 2012;85(3):405.
403	21.	Zhao S, Zhu Y, Schultz RD, et al. Partial Leptin Reduction as an Insulin
404		Sensitization and Weight Loss Strategy. Cell Metab. 2019;30(4):706-719 e706.
405	22.	Sweeney G. Cardiovascular effects of leptin. <i>Nat Rev Cardiol.</i> 2010;7(1):22-29.
406	23.	Jamar G, Caranti DA, de Cassia Cesar H, Masquio DCL, Bandoni DH, Pisani LP.
407		Leptin as a cardiovascular risk marker in metabolically healthy obese:
408		Hyperleptinemia in metabolically healthy obese. <i>Appetite</i> . 2017;108:477-482.
409	24.	Katsiki N, Mikhailidis DP, Banach M. Leptin, cardiovascular diseases and type 2
410		diabetes mellitus. Acta Pharmacol Sin. 2018;39(7):1176-1188.
411	25.	Anaszewicz M, Wawrzenczyk A, Czerniak B, et al. Leptin, adiponectin, tumor
412		necrosis factor alpha, and irisin concentrations as factors linking obesity with
413		the risk of atrial fibrillation among inpatients with cardiovascular diseases.
414		Kardiol Pol. 2019;77(11):1055-1061.
415	26.	Huang Y, Liu Y, Ma Y, et al. Associations of Visceral Adipose Tissue, Circulating
416	20.	Protein Biomarkers, and Risk of Cardiovascular Diseases: A Mendelian
417		Randomization Analysis. Front Cell Dev Biol. 2022;10:840866.
418	27.	Ermakov S, Azarbal F, Stefanick ML, et al. The associations of leptin,
419	27.	adiponectin and resistin with incident atrial fibrillation in women.
419		2016;102(17):1354-1362.
	28.	
421	20.	Lavie CJ, Pandey A, Lau DH, Alpert MA, Sanders P. Obesity and Atrial
422		Fibrillation Prevalence, Pathogenesis, and Prognosis: Effects of Weight Loss
423	20	and Exercise. J Am Coll Cardiol. 2017;70(16):2022-2035.
424	29.	Yang R, Barouch LA. Leptin signaling and obesity: cardiovascular
425	22	consequences. <i>Circ Res.</i> 2007;101(6):545-559.
426	30.	Fukui A, Takahashi N, Nakada C, et al. Role of leptin signaling in the
427		pathogenesis of angiotensin II-mediated atrial fibrosis and fibrillation. Circ
428		Arrhythm Electrophysiol. 2013;6(2):402-409.

- Fukui A, Ikebe-Ebata Y, Kondo H, et al. Hyperleptinemia Exacerbates High-Fat
  Diet-Mediated Atrial Fibrosis and Fibrillation. *J Cardiovasc Electrophysiol*.
  2017;28(6):702-710.
- 432 32. Xiao Q, Gu F, Caporaso N, Matthews CE. Relationship between sleep
  433 characteristics and measures of body size and composition in a
  434 nationally-representative sample. *BMC Obes.* 2016;3:48.
- Ma Y, Peng L, Kou C, Hua S, Yuan H. Associations of Overweight, Obesity and
  Related Factors with Sleep-Related Breathing Disorders and Snoring in
  Adolescents: A Cross-Sectional Survey. Int J Environ Res Public Health.
  2017;14(2).
- 439 34. Muscogiuri G, Barrea L, Annunziata G, et al. Obesity and sleep disturbance:
  440 the chicken or the egg? *Crit Rev Food Sci Nutr.* 2019;59(13):2158-2165.
- 35. Berger S, Polotsky VY. Leptin and Leptin Resistance in the Pathogenesis of
  Obstructive Sleep Apnea: A Possible Link to Oxidative Stress and
  Cardiovascular Complications. Oxid Med Cell Longev. 2018;2018:5137947.
- 44436.Gami AS, Pressman G, Caples SM, et al. Association of atrial fibrillation and445obstructive sleep apnea. *Circulation*. 2004;110(4):364-367.
- 44637.SomersVK,DykenME,ClaryMP,AbboudFM.Sympatheticneural447mechanisms in obstructive sleep apnea.J Clin Invest.1995;96(4):1897-1904.
- 44838.Otto ME, Belohlavek M, Romero-Corral A, et al. Comparison of cardiac449structural and functional changes in obese otherwise healthy adults with450versus without obstructive sleep apnea. Am J Cardiol. 2007;99(9):1298-1302.
- 451 39. Cirillo P, Angri V, De Rosa S, et al. Pro-atherothrombotic effects of leptin in 452 human coronary endothelial cells. *Thromb Haemost.* 2010;103(5):1065-1075.

453

# 454 Figure legends:

- 455 Figure 1: Association of body mass index with atrial fibrillation and mediators in the
- 456 univariable MR analysis.
- 457 **Figure 2:** Association of mediators with the risk of atrial fibrillation in the univariable
- 458 MR analysis.
- 459 Figure 3: Association of body mass index with the risk of atrial fibrillation in the
- 460 multivariate MR analysis.

		OR(95%CI)	p value
Atrial fibrillation	⊢∎⊣	1.41(1.33,1.50)	<0.001
Circulating biomarkers			
Leptin	⊢∎1	1.86(1.68,2.05)	<0.001
Adiponectin	+	1.02(0.99,1.05)	0.258
Resistin	<b>⊢</b> ∎-1	1.09(1.02,1.16)	0.008
C-reactive protein	⊦≡⊣	1.43(1.37,1.49)	<0.001
Metabolic markers			
LDL cholesterol	r <b>≠</b> -1	1.00(0.95,1.06)	0.898
HDL cholesterol	=	0.76(0.73,0.79)	<0.001
Total cholesterol	⊦ <del>≡</del> t	0.96(0.91,1.01)	0.085
Triglycerides	<b>⊢</b> ∎-	1.23(1.16,1.29)	<0.001
Fasting blood glucose	•	0.98(0.96,1.00)	0.015
Systolic blood pressure	<■	0.58(0.35,0.96)	0.032
Diastolic blood pressure	<∎1	0.62(0.46,0.84)	0.002
Comorbidities			
Sleep apnoea	⊢ <b>−</b>	⊣ 2.13(1.93,2.35)	<0.001
Coronary heart disease	⊢∎⊣	1.54(1.43,1.66)	<0.001
Stroke	⊢∎⊣	1.22(1.15,1.30)	<0.001
Chronic kidney disease	-■-1	1.27(1.16,1.40)	<0.001
Hyperthyroidism		1.00(1.00,1.00)	0.971
	0.5 1 1.5 2 <lower higher="" risk="" risk<="" td=""><td>2.5 &gt;</td><td></td></lower>	2.5 >	

		OR(95%CI)	p value
<b>Circulating biomarkers</b>			
Leptin	⊢∎	1.31(1.10,1.55)	0.002
Adiponectin	⊢≢⊣	1.01(0.93,1.10)	0.777
Resistin	∦ <del>≡</del> ⊣	1.06(0.99,1.14)	0.113
C-reactive protein	H <b>⊞</b> -1	1.04(0.97,1.12)	0.307
Metabolic markers			
LDL cholesterol	H <b>e</b> i	1.02(0.98,1.07)	0.267
HDL cholesterol	H	0.98(0.93,1.04)	0.604
Total cholesterol	H	1.03(0.98,1.07)	0.266
Triglycerides	⊦⊷	1.00(0.93,1.07)	0.978
Fasting blood glucose	⊢∎⊣	0.98(0.87,1.11)	0.791
Systolic blood pressure		1.02(1.01,1.02)	<0.001
Diastolic blood pressure	•	1.03(1.02,1.04)	<0.001
Comorbidities			
Sleep apnoea		1.18(1.07,1.30)	0.001
Coronary heart disease	<b>⊦</b> ≡-1	1.11(1.05,1.17)	<0.001
Stroke	$\blacksquare \longrightarrow$	1.88(0.98,3.60)	0.058
Chronic kidney disease	ŀ≢I	1.01(0.96,1.06)	0.728
Hyperthyroidism		13.03(1.64,103.67)	0.015
	0.3 0.6 0.9 1.2 1.5 1.8 2.1 2.4 <lower risk="" riskhigher=""></lower>		





2

<----Lower risk---- ---Higher risk---->

p value

< 0.001

PERM

N/A